Nutriband Inc.

NASDAQ:NTRB

Biotechnology

Healthcare
$4.82 +22.32%

+$0.85 today

Market cap
$58.59M
Beta
1.97
P/E (TTM)
-1.8
EPS (TTM)
-$0.66
52W Low $2.80High $8.63

Volume 0.03M

Average 0.01M

NTRB Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Nutriband Inc.NASDAQ: NTRB

Other Income / Expenses · Q1 FY2026 · quarter ended Apr 2026

Other income / expenses dips below year-ago levels

Q1 FY2026 other income / expenses of $12.4K fell 49.7% year over year, behind the +102.0% change in trailing-twelve-month other income / expenses. Sequentially, it fell 76.5% from the prior quarter.

Context

  • Other income / expenses amounted to 4.3% of revenue in FY2025, down 172.9 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -49.7% toward the trailing-twelve-month pace of +102.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
$12.4K-76.5% QoQ
Last fiscal yearJan 2026
$88.33K+102.3% YoY
LTMApr 2026
$76.1K+102.0% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.7%——
1 year+102.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
88.33K USD
Year-over-year change
+102.3%

Other Income / Expenses vs competitors

How NTRB compares with its peers on the latest reported figures

  • NTRB's LTM Apr 2026 other income / expenses of $76.1K is the 8th highest of the 9 companies compared; the peer median is $4.75M.
  • Its year-over-year change of +102.0% is the 2nd highest of 8, against a peer median of -46.5%.
  • Other income / expenses amounts to 4.2% of revenue for NTRB, versus a peer median of 285.8%.
NTRB Competitors Peer median
Other Income / Expenses for NTRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$189.09M +2976.4%—285.8%
XBITXBiotech Inc.LTM Mar 2026$8.51M +48.5%+125.8%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$5.09M -46.1%+60.9%—
ACETAdicet Bio, Inc.LTM Mar 2026$4.97M -46.6%+24.4%—
ADAGAdagene Inc.LTM Jun 2024$4.52M —-7.1%554.5%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$4.4M -46.5%+144.2%48.1%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$1.47M -57.0%-25.8%—
NTRBNutriband Inc.LTM Apr 2026$76.1K +102.0%—4.2%
GANXGain Therapeutics, Inc.LTM Mar 2026-$601.23K -1940.7%——
Peer median (excluding NTRB) $4.75M-46.5%+42.6%285.8%

Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Jan 2024
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.42M2.08M2.09M2.14M2.04M
Cost of Revenue917.84K1.33M1.22M1.44M1.47M
Gross Profit504.31K750.41K862.11K699.3K566.31K
Gross Margin35.5%36.1%41.3%32.7%27.8%
Research & Development411.38K982.23K1.96M3.12M1.89M
Selling, General & Admin4.02M3.92M3.77M4.27M6.99M
Operating Expenses4.43M4.9M5.73M7.39M8.88M
Depreciation & Amortization318.26K368.96K287.72K285.05K193.8K
EBITDA(5.74M)(4.11M)(5.12M)(10.18M)(8.01M)
EBITDA Margin-403.6%-197.5%-245.6%-475.5%-393.5%
Operating Income(3.93M)(4.15M)(4.87M)(6.69M)(8.32M)
Operating Margin-276.3%-199.5%-233.6%-312.6%-408.4%
Interest Income0016.85K191.67K0
Interest Expense118.42K8.29K75.82K21.41K22.54K
Other Income / Expenses(2.25M)(335.62K)(613.39K)(3.79M)88.33K
Income Before Tax(6.18M)(4.48M)(5.49M)(10.48M)(8.23M)
Pre-Tax Margin-434.3%-215.6%-263.0%-489.9%-404.1%
Income Tax Expense00000
Net Income(8.42M)(4.81M)(5.49M)(10.48M)(8.23M)
Net Margin-592.2%-231.3%-263.0%-489.9%-404.1%
EPS (Basic)(1.06)(0.57)(0.69)(0.99)(2.58)
EPS (Diluted)(1.06)(0.57)(0.69)(0.99)(2.58)
Weighted Avg Shares7.93M8.46M7.95M10.61M11.64M
Weighted Avg Shares (Diluted)7.93M8.46M7.95M10.61M11.64M

Nutriband Inc.

NASDAQ:NTRB

Intrinsic Alpha fair value

Locked

Current Price

$4.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.